Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Palbociclib + Quizartinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Palbociclib||Ibrance||PD0332991||CDK4/6 Inhibitor 9||Ibrance (palbociclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) (PMID: 19874578). Ibrance (palbociclib) is approved in combination with an aromatase inhibitor in postmenopausal patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer, and in combination with Faslodex (fulvestrant) in patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer (FDA.gov).|
|Quizartinib||Vanflyta|AC220||FLT3 Inhibitor 54 KIT Inhibitor 50 PDGFR-alpha Inhibitor 9 RET Inhibitor 39||Vanflyta (Quizartinib) targets both wild-type and mutant FLT3 containing activating internal tandem duplications, as well as PDGFRA, RET, and KIT, which may induce apoptosis and inhibit tumor growth (PMID: 19654408, PMID: 23497317).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 act mut||acute myeloid leukemia||sensitive||Palbociclib + Quizartinib||Preclinical||Actionable||In a preclinical study, Ibrance (palbociclib) and Quizartinib (AC220) were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).||27099147|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|